LUMINA, for Lupus in Minorities: Nature vs. Nurture is a longitudinal outcome study established in response to a request for application from the US National Institute of Arthritis, Musculoskeletal and Skin Disorders (NIAMS) issued in 1993. The LUMINA multiethnic cohort is the result of a collaborative effort between the University of Alabama at Birmingham (UAB), The University of Texas Health Science Center at Houston (UTH) and The University of Puerto Rico Medical Sciences Campus (UPR). The purpose of studying this type of cohort was to determine the underlying causes for the disparate outcomes observed in lupus patients from different ethnic groups, as ethnic minorities seem to experience, overall, less favourable outcomes than the Caucasian majority. It was hypothesized that genetic and socioeconomic factors would be important determinants of these observations. We proposed from the outset to study not only African-American patients from whom significant information was already available in the literature but also Hispanics; in this emergent US minority group, the disease was being recognized also as potentially inflicting serious consequences. The first patients were enrolled at UAB and UTH in 1994 and enrolment continues up to now; UPR joined the study in 2001 in response to a request from NIAMS to diversify the Hispanic group of LUMINA patients. To date, the cohort includes over 600 patients recruited at the three institutions; Hispanic patients from Puerto Rico (PR) and Texas (of Mexican ancestry for the most part) are quite different in their socioeconomic and clinical features. Patients from PR experience, overall, more favourable socioeconomic conditions than those from Texas, tend to have less serious disease manifestations and more favourable outcomes; finally, the PR-Hispanics have also distinct genetic features than the Texas-Hispanics (vide infra). Given these considerations, the data from the Hispanic subsample have been always presented separately for these two ethnic subgroups.
It is impossible to do justice to all the work done with the cohort since its inception, and I am aware that each one of the investigators involved in the study may use a different approach in summarizing not only the salient features of the cohort but also the overall impact of the cohort's findings. Having worked in and directed the project and witnessed the efforts of the dedicated LUMINA research fellows, I will attempt to provide my own perspective about the contribution of LUMINA to the advancement of our knowledge of systemic lupus erythematosus (SLE), vis-à-vis US ethnic minorities.
First and foremost, we feel that lupus in 'Hispanics' has reached a place on the map, so to speak, as this minority population group, particularly the one residing in Texas, tend to present as serious a disease as the African-Americans; 1-4 this is extremely important given that, at the present time, Hispanics in the US constitute the largest and the fastest growing ethnic minority population group, 5 the Mexicanborn and Mexican-American subgroups being its main component.
Second, we have reaffirmed the fact that Hispanics are not a homogenous group from either the socioeconomic, cultural, clinical or genetic basis 6 ; however, we have also shown that the level of acculturation of our Texan-Hispanics population does not seem to have an important influence in the course of the disease. 7 Furthermore, we have shown that there are 'genetic differences' among patients from the ethnic subgroups studied, and there is in particular a significant degree of 'admixture' within them; for example, we have found about 20% African ancestral genes within the Caucasian (European) population, and about the same proportion of Caucasian (European) genes within the African-American population, whereas the Texas-Hispanics have a much larger proportion of Amerindian ancestral genes than the PR-Hispanics who, in turn, have a much larger proportion of African ancestral genes. 8 Third, we have demonstrated that the ACR criteria may accrue over a very variable time period 9 and that early in the disease course, genetic factors (absence of HLA-DRB1*0301 and of HLA-DRB1*01) are important determinants of 'disease activity' 10 ; yet over time, other factors, particularly the socioeconomic ones, emerged as more important predictors of disease activity. 11, 12 More recently, we have shown that the use of angiotensin-converting enzyme (ACE) inhibitors may also exert a modulatory role in disease activity. 13 We have also found that acute disease onset is associated with higher levels of overall disease activity, 14 and that relatively simple laboratory parameters, such as haematocrit, lymphocyte count or erythrocyte sedimentation rate are reliable indicators and can be used as inexpensive biomarkers in the clinical setting. 4, 15, 16 Finally, we have shown that patients and physicians differ significantly in their assessment of disease activity, with patients scoring how they feel (thus, subjective manifestations influencing their assessment) and physicians scoring not only physical findings (presence of rashes, for example) but also laboratory abnormalities which may not be evident at all to the patients. 17 This discrepant appreciation of disease activity may have important clinical and therapeutic consequences; in the first scenario, patients may demand treatments that we rheumatologists do not judge as being indicated whereas, on the basis of the physician's approach, patients may become noncompliant.
Fourth, we have found that 'damage accrual' is a function of age, male gender, Hispanic (Texas) and African-American ethnicities, the weighted ACR criteria, disease activity, specific disease manifestations (thrombocytopenia, hemolytic anaemia, 25 myocarditis, seizures) and glucocorticoid use. [18] [19] [20] [21] [22] [23] [24] [25] Furthermore, once damage occurs it continues to be accrued, yet it may be prevented by hydroxychloroquine, particularly if used before damage starts. 26, 27 We have also demonstrated that Texas-Hispanics tend to accrue damage at a faster pace than patients from the other ethnic groups, 28 and that damage in specific domains of the damage index may have unique associated factors; for example, damage in the pulmonary domain is a function of age, pneumonitis and the presence of anti-RNP antibodies. 29 Relative to specific damage items, osteonecrosis was found to be associated not only with glucocorticoid use but also with the use of cytotoxic agents. 30 Fifth, we have determined that smoking and glucocorticoids are important factors in the occurrence of 'vascular and thrombotic events' in these patients [31] [32] [33] and that C-reactive protein (CRP) serum levels are associated with vascular events; furthermore, we have observed that the GT 21 variant of the CRP gene associates with the occurrence of vascular events in the non-Caucasian patients of the cohort. 34 We have also confirmed that renal involvement, obesity and non-Caucasian ethnicity predispose patients to the occurrence of hypertension. 35 Sixth, that 'mannose binding lectin (MBL) deficient' alleles, purported to be associated with vascular events in Caucasian SLE patients, 36 are not associated with such events in the non-Caucasian LUMINA patients; the association was only significant for the cerebrovascular but not for the peripheral and cardiovascular events 37 further suggesting that genetic association studies conducted in one population group cannot be generalized to others. Furthermore, the MBL genotype does not seem to affect the course and outcome of the disease. 38 Seventh, we have demonstrated that 'renal involvement' occurs more frequently among adolescents 39 and young adults, that it occurs in Texas-Hispanic patients with a frequency comparable to that in the African-Americans, 40 and that such association is determined by genetic rather than socioeconomic fac-tors (African-American and Amerindian ancestral genes) 41 ; furthermore it is evident that persistent proteinuria, which oftentimes heralds the occurrence of end-stage renal disease, also has genetic basis (HLA-DRB1*1503). 42 Finally, we have shown that ACE inhibitors may retard the onset of renal involvement in patients with SLE. 13 Eighth, that 'pregnancy' in the lupus patient, independent of its outcome, may accelerate damage, 43 and the presence of renal disease and the use of high doses of glucocorticoids prior to conception may portend a poor pregnancy outcome 44 ; it has also been shown that age rather than 'menopause' influence damage accrual, 45 that the use of hormonal replacement therapy is not associated with disease activity, 46 and that in patients who have not experienced a previous vascular arterial event and who do not exhibit antiphospholipid antibodies that type of therapy is probably safe. 47 Finally, that 'premature gonadal failure' does not only associate with age and the number of pulses of cyclophosphamide, but also with disease activity. 48 Ninth, we have shown that 'self-reported quality of life', whether assessed with the SF-36 or the instrument derived from the SF-36 for economic evaluations, the SF-6D 49 is primarily due to socioeconomic, psychological and behavioural factors reflecting only to a less extent disease activity or the damage accrued by lupus patients [50] [51] [52] ; we have also found that fatigue is pervasive among SLE patients and that again, is not so much related to disease features, disease activity or damage accumulated as it is to sociodemographic and psychosocial (maladaptive coping styles, poor social support and helplessness) factors. 53 Similarly, obesity is independently associated with 'fibromyalgia' but not with disease activity or damage accrual. 54 In turn, fibromyalgia associates with diminished selfreported physical functioning. 55 Finally, it is evident that self-reported disability is not only associated with the severity of the disease, but also with a low socioeconomic status. 56 Tenth, our findings strengthen the notion that 'poverty', not ethnicity is a predictor of diminished 'survival' in lupus patients from our cohort and that the effect of ethnicity only becomes evident once poverty is removed from multivariable models 57, 58 ; this finding has been replicated numerous times, and underscores the importance of socioeconomic determinants in the ultimate outcome of this disease as noted by other investigators. 59 We have also recognized, in conjunction with investigators from the Carolina Lupus Cohort, that the burden of lupus may not be fully appreciated as underrecording it as a cause of death on vital statistics records is not uncommon. 60 Finally, we have examined the role of 'hydroxychloroquine' in survival, utilizing propensity score analyses and a nested case-control design, and found that indeed hydroxychloroquine is a protective factor of this outcome 61 ; these data support findings published by Ruiz-Irastorza, 62 and the unpublished data from GLADEL (for Grupo Latino Americano de Estudio de Lupus or Latino American Group for the Study of Lupus). In my view, these data are the LUMINA cohort's findings of greatest relevance and applicability for the management of patients with SLE. We are currently examining the role of hydroxychloroquine in preventing damage in specific domains of the damage index as suggested by preliminary analyses. 63 From an operational perspective, LUMINA not only has reiterated the difficulties in the recruitment of patients for a longitudinal observational study but also the potential problem of patient retention in the cohort; traditionally in the US, and in great part due to the legacy of the Tuskegee study, African-Americans have been, and still are, less likely to participate not only in randomized clinical trials but also in longitudinal observational studies [64] [65] [66] [67] ; in addition, these patients along with the Texan-Hispanics, tend to be lost to follow-up more frequently, and to be noncompliant with their study visits than the Caucasians and the PR-Hispanics. 68, 69 Obviously, the problems with recruitment and retention will have variable impact in the generalizability of the data generated. Another lesson from LUMINA, is the need to constitute, along with the database, a robust repository of biological specimens (plasma, sera, DNA) which can be used later in studies examining hypotheses not anticipated at the time a cohort is initially started. The success of a cohort depends not only on the commitment of the investigators and continuous adequate funding but also on the quality of the research coordinators whose role is crucial for the day-to-day execution of the different research-related activities (patients' visits, data acquisition and entry, quality control and communication, among others); I am personally grateful to them at all participating institutions.
In short, we have shown the importance of both 'genetic' and 'non-genetic' factors influencing the 'course' and 'outcome' of SLE. Ethnic minorities, particularly African-Americans and Hispanics with a significant proportion of Amerindian ancestry, tend to experience the disease more frequently and to face less favourable outcomes. Renal disease seems to be importantly determined by genetic factors; however, in terms of the final outcome, socioeconomic factors associated with ethnic minority status tend to be quite relevant. While we should work at the patient and family level to improve the outcome of patients afflicted with this disorder, 70 changes at the societal level 71 will be necessary to produce a significant long-lasting impact in the lives of patients with this, oftentimes, debilitating disorder.
Thanks to the enthusiasm and dedication of John D Reveille, MD, from UTH, who was instrumental in securing our initial funding; the exemplary commitment of Luis M. Vilá, MD, from UPR; the methodological and analytical capabilities of Gerald McGwin, Jr, PhD; the contributions of other faculty at UAB (Jeffrey Roseman, PhD, Barri Fessler, MD, MSPH and Holly Bastian, MD, MSPH) and the cadre of research fellows (Table 1) we have enjoyed mentoring over the years; they have been the source of new ideas and have used the perseverance needed to execute and take them to completion (including a plethora of publications). LUMINA could have not been as productive as it has been without them; I will forever be indebted to them and to the generosity of Mrs Katherine Snider, Rheuminations, Inc., who believed in our endeavour and has supported their work over the last few years. 
